Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
131.8 USD | +4.96% | +6.38% | +20.85% |
Mar. 27 | S&P 500 Closes at Record High Ahead of Thursday's Economic Data | MT |
Mar. 27 | Sector Update: Health Care Stocks Advance Late Afternoon | MT |
Financials (USD)
Sales 2024 * | 63.76B | Sales 2025 * | 68.02B | Capitalization | 334B |
---|---|---|---|---|---|
Net income 2024 * | 19.74B | Net income 2025 * | 22.11B | EV / Sales 2024 * | 5.54 x |
Net Debt 2024 * | 19.56B | Net Debt 2025 * | 7.5B | EV / Sales 2025 * | 5.02 x |
P/E ratio 2024 * |
16.8
x | P/E ratio 2025 * |
14.6
x | Employees | 71,000 |
Yield 2024 * |
2.36% | Yield 2025 * |
2.5% | Free-Float | 70.71% |
Latest transcript on Merck & Co., Inc.
1 day | -0.53% | ||
1 week | +6.38% | ||
Current month | +3.62% | ||
1 month | +2.11% | ||
3 months | +22.01% | ||
6 months | +26.76% | ||
Current year | +20.85% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 14-03-31 |
Director of Finance/CFO | 55 | 89-12-31 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 07-11-26 |
Pamela Craig
BRD | Director/Board Member | 67 | 15-08-31 |
Inge Thulin
BRD | Director/Board Member | 69 | 18-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
14.34% | 227 M€ | +6.90% | - | |
5.61% | 18 M€ | +7.01% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-27 | 131.8 | +4.96% | 16,061,581 |
24-03-26 | 125.5 | +0.17% | 8,864,402 |
24-03-25 | 125.3 | +1.18% | 7,605,755 |
24-03-22 | 123.8 | +0.19% | 7,022,502 |
24-03-21 | 123.6 | -0.19% | 8,156,305 |
Delayed Quote Nyse, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.85% | 334B | |
+33.50% | 701B | |
+26.24% | 571B | |
+0.78% | 381B | |
+16.38% | 319B | |
+2.47% | 210B | |
+1.53% | 210B | |
-6.79% | 201B | |
-3.51% | 157B | |
-0.60% | 153B |